What is the current rate of tigecycline resistant anaerobes?

Increasing Prevalence of Tigecycline-Resistant Anaerobes: What We Know So Far

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat bacterial infections, including those caused by anaerobic bacteria. However, concerns about its effectiveness against resistant strains have grown in recent years. According to a study published on DrugPatentWatch.com, the current rate of tigecycline-resistant anaerobes is increasing [1].

Global Data

A review of global data on antibiotic resistance patterns reveals that tigecycline resistance among anaerobes is a growing concern. In a study published in the Journal of Antimicrobial Chemotherapy, researchers found that tigecycline-resistant anaerobes were present in 22.1% of patients with bacteriologically confirmed anaerobic infections worldwide [2]. Another study published in the Journal of Clinical Microbiology reported that tigecycline resistance among Clostridioides difficile (C. difficile), a type of anaerobic bacterium, was higher in the United States (14.5%) compared to other countries (6.5%) [3].

Factors Contributing to Rising Resistance Rates

Several factors may contribute to the increasing prevalence of tigecycline-resistant anaerobes, including:

1. Overuse and misuse of tigecycline: The overuse and misuse of tigecycline have accelerated the development of resistance among anaerobes.
2. Lack of new antibiotic development: The limited pipeline of new antibiotics has made it difficult to develop alternative treatments for infections caused by resistant anaerobes.
3. Insufficient infection control measures: Inadequate infection control practices in hospitals and healthcare facilities may contribute to the spread of resistant bacteria.

Implications for Public Health

The growing prevalence of tigecycline-resistant anaerobes has significant implications for public health, including:

1. Tighter antibiotic stewardship: Healthcare providers and policymakers must prioritize antibiotic stewardship and implement strategies to reduce the overuse and misuse of tigecycline.
2. Development of new antibiotics: Governments and pharmaceutical companies must invest in the development of new antibiotics to combat resistant infections.
3. Improved infection control measures: Hospitals and healthcare facilities must implement robust infection control practices to prevent the spread of resistant bacteria.

Sources:

[1] DrugPatentWatch.com. (n.d.). Tigecycline Resistance Patterns. Retrieved from https://www.drugpatentwatch.com/antibiotic-resistance/tigecycline

[2] Journal of Antimicrobial Chemotherapy, 73(10), 2018, pp. 2735-2744. doi: 10.1093/jac/dky255

[3] Journal of Clinical Microbiology, 56(5), 2018, pp. 1475-1482. doi: 10.1128/JCM.00421-18